- Trial phase
- Approved (marketed)
- Time to market
- Already marketed, FDA approval June 30, 2006; on the market for ~20 years.
- Why 3/10
- No hard, dated binary catalyst for Lucentis itself in the next ~12 months, it was approved in 2006 and has no pending PDUFA or pivotal readout, so it scores 3 as a mature, already-marketed drug whose defining binary passed two decades ago.
Correct the filing hint: Lucentis is a Genentech/Roche drug; Novartis only held ex-US commercialization rights. For a non-medical investor this is not a catalyst stock, watch instead how fast Harrow's interchangeable ranibizumab biosimilar Byooviz (US launch July 1, 2026) and longer-acting rivals like faricimab eat into remaining Lucentis share, visible only in quarterly Roche/Novartis ophthalmic-sales lines.
Price Chart
Executive Summary
Lucentis (ranibizumab) is a ~20-year-old anti-VEGF eye injection developed by Genentech/Roche (US rights) with Novartis (NVS) holding ex-US commercialization rights, SecBot's catalyst dataset attributes the June 30, 2006 FDA approval to RHHBY. It was one of the most successful ophthalmic drugs ever, but its patents have long expired and it now faces interchangeable biosimilars (Harrow launched Byooviz in the US on July 1, 2026), cheaper off-label Avastin, and longer-dosing competitors including Roche's own faricimab. It remains the standard-of-care comparator in dozens of ongoing trials, but for Roche it is a small, declining part of a mega-cap portfolio with no scheduled regulatory catalyst, so the stock impact is minimal.
How It Works
Ranibizumab is a small fragment of a lab-made antibody that is injected directly into the eyeball. It grabs and disables a protein called VEGF-A that drives abnormal, leaky blood vessels in the retina, the underlying problem in wet age-related macular degeneration, diabetic macular edema and other sight-threatening eye conditions, drying up the leakage that destroys central vision. It typically requires monthly eye injections, which is its main weakness versus newer competitors.
Trial Status
Approved since 2006 and now the reference standard in retinal disease: ranibizumab is used as the active comparator arm in multiple current Phase 2/3 trials (Roche's faricimab myopic-CNV Phase 3 completed 2026-05-22 with results pending; EyeBiotech EYE103 Phase 3 in diabetic macular edema with est. primary completion Sept 2026; AbbVie's RGX-314 gene-therapy Phase 2). An interchangeable biosimilar (Byooviz, ranibizumab-nuna) was commercially launched in the US by Harrow on July 1, 2026.
The Two-Sided Case
Upcoming Catalysts
- No Lucentis-specific FDA/PDUFA catalyst scheduled; watch quarterly Roche (RHHBY) and Novartis (NVS) reporting for ophthalmology/ranibizumab sales trends (e.g., NVS 6-K filed 2026-07-21).
- Biosimilar uptake: Harrow Byooviz US commercial launch (2026-07-01) and ASRS 2026 data (2026-07-20), monitor share gains and pricing.
- Competitor readouts where ranibizumab is the comparator arm: EyeBiotech EYE103 Phase 3 DME trial (est. primary completion Sept 2026, NCT06571045) and Roche faricimab myopic-CNV Phase 3 (completed 2026-05-22, results pending, NCT06176352).
- EMA opinions on ranibizumab products: Susvimo (2026-07-24) and Vislyfa (2026-05-22) EPAR statuses.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report